Colonial Trust Advisors Sells 450 Shares of Solventum Co. (NYSE:SOLV)

Colonial Trust Advisors cut its stake in shares of Solventum Co. (NYSE:SOLV) by 51.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 431 shares of the company’s stock after selling 450 shares during the quarter. Colonial Trust Advisors’ holdings in Solventum were worth $28,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of SOLV. Modus Advisors LLC purchased a new stake in Solventum during the fourth quarter valued at about $25,000. Stonebridge Financial Group LLC bought a new stake in Solventum in the 4th quarter worth approximately $26,000. Crews Bank & Trust purchased a new stake in Solventum in the fourth quarter worth approximately $32,000. Synergy Asset Management LLC bought a new position in Solventum during the fourth quarter valued at approximately $35,000. Finally, Spire Wealth Management purchased a new position in shares of Solventum during the fourth quarter worth approximately $37,000.

Solventum Stock Down 4.8 %

Shares of NYSE:SOLV opened at $65.30 on Friday. Solventum Co. has a 1 year low of $47.16 and a 1 year high of $85.92. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83. The stock’s 50-day moving average is $74.36 and its 200 day moving average is $71.72. The company has a market cap of $11.30 billion and a PE ratio of 23.75.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on SOLV shares. Mizuho upped their price objective on shares of Solventum from $70.00 to $82.00 and gave the company a “neutral” rating in a research note on Monday, March 3rd. Morgan Stanley raised their price objective on Solventum from $73.00 to $80.00 and gave the company an “equal weight” rating in a research note on Wednesday, March 5th. The Goldman Sachs Group lifted their price objective on Solventum from $63.00 to $71.00 and gave the stock a “sell” rating in a report on Monday, March 3rd. Wells Fargo & Company increased their target price on Solventum from $73.00 to $75.00 and gave the company an “equal weight” rating in a report on Friday, February 28th. Finally, Bank of America lifted their price target on Solventum from $80.00 to $85.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 26th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $79.86.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.